Home » Topics » Nephrology, BioWorld Science

Nephrology, BioWorld Science
RSS

RenaZorb begins testing in animals

Dec. 12, 2002

European approval for Avodart for benign prostatic hyperplasia

Dec. 11, 2002

Lilly and Boehringer Ingelheim sign cocommercialization agreements for duloxetine

Dec. 10, 2002

Lilly Icos presents new PDE5 inhibitors for male and female sexual dysfunction

Dec. 9, 2002

Marketing authorization application submitted for Striant in U.K.

Dec. 9, 2002

ZP-120 completes phase I trial

Dec. 9, 2002

Kissei licenses KUC-7483 to Boehringer Ingelheim

Dec. 2, 2002

Ortho Biotech licenses bone morphogenetic protein technology

Nov. 29, 2002

Effective agents for nephritis without cardiovascular side effects designed at Tanabe Seiyaku

Nov. 28, 2002

Renoprotective effects of ALT-711 in diabetic rats

Nov. 27, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...